Podlesak Dennis 4
4 · Syndax Pharmaceuticals Inc · Filed Aug 18, 2025
Insider Transaction Report
Form 4
Podlesak Dennis
Director
Transactions
- Exercise/Conversion
Stock Options (Right to buy)
2025-08-15−14,400→ 0 totalExercise: $7.20Exp: 2025-08-18→ Common Stock (14,400 underlying) - Exercise/Conversion
Stock Options (Right to buy)
2025-08-18−19,200→ 0 totalExercise: $7.20Exp: 2025-08-20→ Common Stock (19,200 underlying) - Sale
Common Stock
2025-08-14$14.19/sh−19,200$272,521→ 191,763 total - Sale
Common Stock
2025-08-18$15.84/sh−19,200$304,170→ 191,763 total - Sale
Common Stock
2025-08-15$15.54/sh−19,200$298,408→ 191,763 total - Exercise/Conversion
Common Stock
2025-08-15$7.20/sh+19,200$138,240→ 210,963 total - Exercise/Conversion
Stock Options (Right to buy)
2025-08-15−4,800→ 0 totalExercise: $7.20Exp: 2025-08-20→ Common Stock (4,800 underlying) - Exercise/Conversion
Common Stock
2025-08-14$7.20/sh+19,200$138,240→ 210,963 total - Exercise/Conversion
Common Stock
2025-08-18$7.20/sh+19,200$138,240→ 210,963 total - Exercise/Conversion
Stock Options (Right to buy)
2025-08-14−19,200→ 0 totalExercise: $7.20Exp: 2025-08-18→ Common Stock (19,200 underlying)
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person solely covering equity grants with expiration dates prior to August 21, 2025. Following the sales reported in this Form 4, the Reporting Person has a total of 135,000 options to purchase shares of common stock that are vested and immediately exercisable and no unvested options to purchase shares of common stock.
- [F2]The sale prices ranged from $13.30 to $14.80.
- [F3]The sale prices ranged from $14.88 to $15.91.
- [F4]The sale prices ranged from $15.61 to $16.00.
- [F5]This option is fully vested.